Medicine
Urocit-k 15 mEq extended-release tablet
Urocit-k 15 mEq extended-release tablet is a prescription medicine containing Potassium citrate for oral use, marketed by Mission Pharmacal, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store in a tight container.
Key facts
- Active ingredient (INN)
- Potassium citrate
- Brand
- Urocit-k
- Strength
- 15 mEq
- Dosage form
- Extended-release tablet
- Route
- Oral
- Packs
- 100 tablets
- Marketing authorisation holder
- Mission Pharmacal
- Manufacturer
- Mission Pharmacal
- Origin register
- US FDA, United States
- Storage
- Store in a tight container.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- A12BA02 Potassium citrate
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 27 January 2010
- Identifiers
- RxCUI 199376, 199381, 603281 +3DailyMed set ID 72cdea1b-2240-41db-987d-86d5c6aaa978NDC 0178-0615Application NDA019071
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 100 tablet, extended release in 1 bottle | 0178-0615-01 | Mission Pharmacal | 27 January 2010 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 30 August 1985 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Potassium citrate 15 mEq extended-release tablet.
Other strengths and forms of Potassium citrate
Clinical summary
Potassium citrate is an anti-coagulant indicated for the management of renal tubular acidosis, among other approved uses. It is available as extended-release tablets and tablets for oral use. MedsAcross supplies Potassium citrate for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Potassium citrateFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Potassium Citrate prescribing information (Biocomp Pharma) · U.S. National Library of Medicine, DailyMed
Need Urocit-k 15 mEq extended-release tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.